On the Issue of the Treatment of Children with Allergic Diseases

О. О. Chorna1, Т. P. Binda2

1Sumy City Children’s Clinical Hospital named after Saint Zinaida, Sumy, Ukraine

2Chair of Pediatrics, Faculty of Postgraduate Education, Medical Institute, Sumy State University, Sumy, Ukraine)

Topical Issues of Theoretical Medicine. In: Program and Abstracts of the Research & Practice Conference of Students, Young Scientists, Physicians, and Professors, devoted to the Science Day of Ukraine 20 March 2009. April 23–24, Sumy, Ukraine; SumGU, 2009:87–88 (in Ukrainian)

Keywords: adsorbent, allergic diseases, dermal-respiratory syndrome, enterosorbent, Enterosgel


A gradual growth in the incidence of allergic diseases has been observed in children since the second half of the 20th century [1]. According to epidemiological studies, 20% of the world population suffer from allergic diseases [2]. This is largely due to the impaired ecological balance, wide use of domestic and agricultural chemicals, common (and frequently uncontrolled) use of antibiotic therapy, vaccine prophylaxis of pediatric infections, and early discontinuation of breastfeeding. Furthermore, allergic diseases have been becoming considerably “younger” in the last decade, i.e. they have their onset at an earlier age and tend to more frequently have severe clinical forms. Therefore, allergy in children is one of the most topical problems in modern clinical medicine. Lability and functional immaturity of many organs and systems are characteristic of young children, being responsible for the specifics of the immune regulation processes. This often results in sensitization, resistance to conventional, standard pharmacological therapy, and difficulties in choosing the optimal treatment strategy for the disease.

Therefore, the search for novel drugs and treatments for diseases associated with immune status impairment is a topical issue. Normalization of gastrointestinal function is an essential element in the pathogenetic treatment. Inclusion of intestinal adsorbents (enterosorbents), in particular Enterosgel, in the combination therapy of allergic diseases is one of the promising approaches. This study was carried out with the aim to evaluate the effectiveness, tolerability, and safety of Enterosgel therapy in the treatment of children with dermal-respiratory syndrome.

Materials and methods

We examined a total of 56 children aged from 3 to 17 years and suffering from dermal-respiratory syndrome in the period from 2006 to 2008. Among them, 27 children were given Enterosgel as part of their combination therapy (experimental group), while the other 29 patients were administered conventional therapy alone (control group).

All children aged over 5 years underwent allergological examination. The dermalrespiratory syndrome had become exacerbated because of domestic allergens, plant pollen, house dust, or use of medicines (most commonly antibiotics). Food allergy was observed in more than one-third of all evaluated children, and the overwhelming majority of them had multiple allergies, which was probably indicative of a pseudo-allergic mechanism of development underlying their disease. This reflected a need to undertake a comprehensive complex of therapeutic measures with the aim to correct all elements and stages in the development of allergic diseases.

Results and discussion

Results obtained in the study groups demonstrated that the inclusion of the intestinal adsorbent Enterosgel in the combination treatment programme promoted fast regression of the manifestations of dermalrespiratory syndrome:

  • reduction of rash and skin edema (85%) by the 5th day of the combination therapy;
  • improvement of dyspepsia: normalization of stools, elimination of nausea and vomiting.

At the same time, the children in the control group had less pronounced improvement in the dermal-respiratory syndrome; any improvement was achieved only in 27.6% of these subjects. Relief of the symptoms of dermal-respiratory syndrome, abdominal syndrome, and dyspepsia was achieved as late as on the 7th or 8th day of the combination therapy.

All children tolerated Enterosgel therapy well. No patients experienced adverse drug reactions or refused to have this treatment.


Therefore, the reported study confirmed the pathogenetic justification for and benefits of Enterosgel therapy in the combination therapy of allergic diseases in children.


  1. Beasley RKU, von Mutius E, Pearce N, International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee: Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet. 1998;351:1225–1232.
  2. Prevention of Allergy and Allergic Asthma. Geneva, World Health Organization, 2003.